CASP3 and metabolic dysfunction-associated steatotic liver disease: For nonalcoholic fatty liver disease (NAFLD), Ariel E Feldstein et al. (Feldstein et al., 2003) emphasized the increase in caspase-3/7 activity in patients with nonalcoholic steatohepatitis (NASH), as well as a significant increase in hepatocyte apoptosis and FAS receptors.